Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAX2398 + 5-FU/LV in Metastatic Pancreatic Cancer
NCT02697058Phase 2Completed
- Sponsor
- Servier
- Start
- Mar 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan (3 arms), sponsored by Servier. Primary endpoint: Progression Free Survival up to 22 months. Started Mar 2016; status: completed.
02
Drugs
irinotecan
Beyond the preview
Go deeper on NCT02697058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02697058.